The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Madison Asset Management LLC significantly increased its position in Charles River Laboratories International, Inc. (NYSE:CRL) during the third quarter, acquiring 12,366 shares. This strategic investment was valued at approximately $1.935 million, signaling confidence in the company's prospects. Concurrently, other institutional investors also made adjustments to their holdings in CRL shares, reflecting broader market interest. Financial analysts maintain a "Moderate Buy" rating for CRL, with an average price target set at $209.46. This target suggests a potential upside from current levels, reinforcing a positive outlook for the biopharmaceutical services provider. The institutional buying activity, coupled with favorable analyst sentiment, underscores a bullish perspective on Charles River Laboratories' future performance.
Sign in to access this content
Sign In